Hyperoside alleviates postmenopausal osteoporosis via regulating miR‐19a‐5p/IL‐17A axis

Abstract

AbstractProblemPostmenopausal osteoporosis (PMO) is a common osteoporosis. Hyperoside (Hyp), a natural flavonoid compound, has anti‐osteoporotic effects, but the underlying mechanisms remain poorly understood. Inflammatory cytokine IL‐17A is upregulated in PMO and plays vital roles in bone loss, but the upstream regulatory factors and mechanisms are still unknown.Method of studyTwenty PMO patients and 20 healthy control subjects were included to analyze IL‐17A expression changes and screen dys‐regulated miRNAs in the peripheral blood of PMO patients. miR‐19a‐5p mimics and inhibitor were transfected into RAW264.7 osteoclasts, and injected into bilateral ovariectomized (OVX) mice to explore the regulatory effect of miR‐19a‐5p on IL‐17A. OVX mice were randomly grouped and treated with different doses of Hyp to uncover the effective targets for the medicine in PMO disease.ResultsMiR‐19a‐5p was downregulated in PMO patients and the expression level was negatively correlated with that of IL‐17A. miR‐19a‐5p could directly bind to the 3′UTR of IL‐17A and regulate its expression. Both in vitro and in vivo studies demonstrated that miR‐19a‐5p mimics decreased the expression of IL‐17A, RANK and Cathepsin K, while miR‐19a‐5p inhibitor significantly increased the expression of IL‐17A, RANK, and Cathepsin K. Importantly, the Hyp could improve bone structure of OVX mice by enhancing miR‐19a‐5p‐mediated IL‐17A downregulation.ConclusionOverall, these data demonstrated that miR‐19a‐5p/IL‐17A axis might serve as novel therapeutic candidate for PMO. Hyp could relieve bone resorption by targeting the miR‐19a‐5p/IL‐17A axis in OVX mice and exhibited prospective for the treatment of PMO.